Rexahn’s CEO transitions to CSO

Tuesday, March 8, 2011

Rexahn Pharmaceuticals, a clinical-stage pharmaceutical company commercializing oncology and CNS therapeutics, said Dr. Chang Ahn has decided to transition his role as chief executive officer to chief science officer of Rexahn. He will continue to serve as chairman of Rexahn’s board of directors.

[Read More]